Cargando…
Diallyl Disulfide Induces Chemosensitization to Sorafenib, Autophagy, and Cell Cycle Arrest and Inhibits Invasion in Hepatocellular Carcinoma
Hepatocellular carcinoma is the seventh most common type of cancer in the world, with limited treatment options. A promising strategy to treat cancer is to associate chemotherapeutics and plant bioactive compounds. Here, we examined whether diallyl disulfide (DADS; 50–200 μM) and sorafenib (SORA; 8...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788602/ https://www.ncbi.nlm.nih.gov/pubmed/36559076 http://dx.doi.org/10.3390/pharmaceutics14122582 |
_version_ | 1784858793911255040 |
---|---|
author | Machado, Ana Rita Thomazela Tuttis, Katiuska Santos, Patrick Wellington da Silva Aissa, Alexandre Ferro Antunes, Lusânia Maria Greggi |
author_facet | Machado, Ana Rita Thomazela Tuttis, Katiuska Santos, Patrick Wellington da Silva Aissa, Alexandre Ferro Antunes, Lusânia Maria Greggi |
author_sort | Machado, Ana Rita Thomazela |
collection | PubMed |
description | Hepatocellular carcinoma is the seventh most common type of cancer in the world, with limited treatment options. A promising strategy to treat cancer is to associate chemotherapeutics and plant bioactive compounds. Here, we examined whether diallyl disulfide (DADS; 50–200 μM) and sorafenib (SORA; 8 μM), either alone or in combination, were toxic to hepatocellular carcinoma cells (HepG2) in vitro. We assessed whether DADS and/or SORA induced cell death (LIVE/DEAD assay and autophagy) and cell cycle changes (flow cytometry), altered expression of key genes and proteins (RT-qPCR and Western blot), and modulated tumorigenesis signatures, such as proliferation (clonogenic assay), migration (wound healing), and invasion (inserts). The DADS + SORA combination elicited autophagic cell death by upregulating LC3 and NRF2 expression and downregulating FOS and TNF expression; induced the accumulation of cells in the G1 phase which thereby upregulated the CHEK2 expression; and inhibited invasion by downregulating the MMP2 expression. Predictive analysis indicated the participation of the MAPK pathway in the reported results. The DADS + SORA combination suppressed both cell invasion and clonogenic survival, which indicated that it dampened tumor growth, proliferation, invasion, and metastatic potential. Therefore, the DADS + SORA combination is a promising therapy to develop new clinical protocols. |
format | Online Article Text |
id | pubmed-9788602 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97886022022-12-24 Diallyl Disulfide Induces Chemosensitization to Sorafenib, Autophagy, and Cell Cycle Arrest and Inhibits Invasion in Hepatocellular Carcinoma Machado, Ana Rita Thomazela Tuttis, Katiuska Santos, Patrick Wellington da Silva Aissa, Alexandre Ferro Antunes, Lusânia Maria Greggi Pharmaceutics Article Hepatocellular carcinoma is the seventh most common type of cancer in the world, with limited treatment options. A promising strategy to treat cancer is to associate chemotherapeutics and plant bioactive compounds. Here, we examined whether diallyl disulfide (DADS; 50–200 μM) and sorafenib (SORA; 8 μM), either alone or in combination, were toxic to hepatocellular carcinoma cells (HepG2) in vitro. We assessed whether DADS and/or SORA induced cell death (LIVE/DEAD assay and autophagy) and cell cycle changes (flow cytometry), altered expression of key genes and proteins (RT-qPCR and Western blot), and modulated tumorigenesis signatures, such as proliferation (clonogenic assay), migration (wound healing), and invasion (inserts). The DADS + SORA combination elicited autophagic cell death by upregulating LC3 and NRF2 expression and downregulating FOS and TNF expression; induced the accumulation of cells in the G1 phase which thereby upregulated the CHEK2 expression; and inhibited invasion by downregulating the MMP2 expression. Predictive analysis indicated the participation of the MAPK pathway in the reported results. The DADS + SORA combination suppressed both cell invasion and clonogenic survival, which indicated that it dampened tumor growth, proliferation, invasion, and metastatic potential. Therefore, the DADS + SORA combination is a promising therapy to develop new clinical protocols. MDPI 2022-11-24 /pmc/articles/PMC9788602/ /pubmed/36559076 http://dx.doi.org/10.3390/pharmaceutics14122582 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Machado, Ana Rita Thomazela Tuttis, Katiuska Santos, Patrick Wellington da Silva Aissa, Alexandre Ferro Antunes, Lusânia Maria Greggi Diallyl Disulfide Induces Chemosensitization to Sorafenib, Autophagy, and Cell Cycle Arrest and Inhibits Invasion in Hepatocellular Carcinoma |
title | Diallyl Disulfide Induces Chemosensitization to Sorafenib, Autophagy, and Cell Cycle Arrest and Inhibits Invasion in Hepatocellular Carcinoma |
title_full | Diallyl Disulfide Induces Chemosensitization to Sorafenib, Autophagy, and Cell Cycle Arrest and Inhibits Invasion in Hepatocellular Carcinoma |
title_fullStr | Diallyl Disulfide Induces Chemosensitization to Sorafenib, Autophagy, and Cell Cycle Arrest and Inhibits Invasion in Hepatocellular Carcinoma |
title_full_unstemmed | Diallyl Disulfide Induces Chemosensitization to Sorafenib, Autophagy, and Cell Cycle Arrest and Inhibits Invasion in Hepatocellular Carcinoma |
title_short | Diallyl Disulfide Induces Chemosensitization to Sorafenib, Autophagy, and Cell Cycle Arrest and Inhibits Invasion in Hepatocellular Carcinoma |
title_sort | diallyl disulfide induces chemosensitization to sorafenib, autophagy, and cell cycle arrest and inhibits invasion in hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788602/ https://www.ncbi.nlm.nih.gov/pubmed/36559076 http://dx.doi.org/10.3390/pharmaceutics14122582 |
work_keys_str_mv | AT machadoanaritathomazela diallyldisulfideinduceschemosensitizationtosorafenibautophagyandcellcyclearrestandinhibitsinvasioninhepatocellularcarcinoma AT tuttiskatiuska diallyldisulfideinduceschemosensitizationtosorafenibautophagyandcellcyclearrestandinhibitsinvasioninhepatocellularcarcinoma AT santospatrickwellingtondasilva diallyldisulfideinduceschemosensitizationtosorafenibautophagyandcellcyclearrestandinhibitsinvasioninhepatocellularcarcinoma AT aissaalexandreferro diallyldisulfideinduceschemosensitizationtosorafenibautophagyandcellcyclearrestandinhibitsinvasioninhepatocellularcarcinoma AT antuneslusaniamariagreggi diallyldisulfideinduceschemosensitizationtosorafenibautophagyandcellcyclearrestandinhibitsinvasioninhepatocellularcarcinoma |